Tom Hochuli Named CEO of Current Biologics

The board of Current Biologics selected Tom Hochuli as chief executive officer of the startup company, which is focused on providing cell and gene therapy manufacturing and development services to the biotechnology and pharmaceutical industries. Current Biologics was established as a joint venture of Cincinnati Children’s and CTI Clinical Trial & Consulting Services.

“Tom Hochuli brings more than 30 years of leadership experience in the biologics, pharmaceutical, medical device, and consumer products industries,” said Steve Davis, MD, president and CEO of Cincinnati Children’s. “His expertise will guide Current Biologics as the company recruits talent and builds a state-of-the-art current Good Manufacturing Practice facility capable of producing multiple vectors for cell and gene therapy research. With Tom’s leadership, Current Biologics will ensure that our patients – and others around the world – have access to the most innovative and effective medical therapies.” 

For the last two years, Hochuli has been CEO of Vibalogics Holdings LLC, a virotherapy process development and manufacturing organization near Boston. He previously had a leadership role with the Lonza cell and gene therapy manufacturing facility in Houston.

“Current Biologics will support Cincinnati Children’s efforts as one of the world’s leading medical centers committed to scientific research and innovation,” Hochuli said. “I’m pleased to have a role in helping the medical center expand the services of its Translational Core Laboratory. We will leverage this experience in collaboration with CTI, a leading global clinical research organization, creating a Contract Development and Manufacturing Organization that facilitates new treatments and ultimately saves lives.”

WittKieffer’s Morten Nielsen and Mindy Steiger led this search.

Read the full announcement.